Neurogen Corporation

Cunyu Zhang

Raymond F Horvath

Taeyoung Yoon

Kevin J Hodgetts

Ping Ge

Dario Doller

Stéphane De Lombaert

Bernd Kaiser

Yasuchika Yamaguchi

Lu Yan Zhang

Stėphane DeLombaert

Xuechun Zhang

Jim Darrow

Arylpyrazine compounds are provided, including arylpyrazines that can bind with high affinity and high selectivity to CRFreceptors, including human CRFreceptors. The invention thus includes methods for treatment of disorders and diseases associated with CRFreceptors, including CNS-related disorders and diseases, particularly affective disorders and diseases, and acute and chronic neurological disorders and diseases.

Substituted arylpyrazines

Novel 5-substituted-2-arylpyrazine compounds are provided. Such compounds can act as selective modulators or CRF receptors. Compounds of the invention are provided by the following formula:  The 5-substituted-2-arylpyrazine compounds provided herein are useful in the treatment of a number of CNS and periphercal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds provided are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.

5-substituted-2-arylpyrazines

Growing community of inventors

Morrisville, NC, United States of America

Cunyu Zhang